Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AQST vs HRMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HRMY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

HRMY Overall Winner 6-Pillar Tally: AQST 0 – 6 HRMY Matrix Metrics: AQST 0 – 10 HRMY

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin), whereas HRMY carries 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin).

  • Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile HRMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQST vs HRMY
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23
HRMY NASDAQ Head-to-Head Winner
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
TTM Revenue $989M
Forward P/E 5.4x
Beta / 30D Vol 0.55β · 38% Vol
Unified Composite Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.1%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $34.97 · SMA50: $37.77

6-Pillar Scorecard Institutional Category Breakdown (AQST 0 – 6 HRMY)

Columns: Metric · AQST · HRMY
1. Valuation Multiples HRMY
Forward P/E N/M 5.4x
Trailing P/E N/M 10.9x
PEG Ratio N/M N/M
EV / Revenue 8.9x 1.5x
2. Growth & Scale HRMY
Revenue Growth (YoY) -41.0% +12.3%
Earnings Growth (YoY) +0.0% -6.9%
TTM Revenue (USD) $49M $989M
Market Cap $465.7M $1.9B
3. Profitability & Quality HRMY
Gross Margin 65.3% 74.0%
Operating Margin -114.1% 22.2%
Net Profit Margin -162.3% 18.1%
Return on Equity (ROE) 0.0% 18.7%
4. Balance Sheet & Cash Flow HRMY
Cash Generation (TTM) -$41M $323M
Cash Flow Margin -83.3% 32.6%
Net Cash / Leverage $32M Net Cash $498M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HRMY
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 87.9% (64th %ile) 72.4% (11th %ile)
Put/Call OI Skew 0.98x (Balanced) 4.40x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat HRMY
OpEx & R&D Intensity N/A 51.8% of Rev ($512M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQST (0) vs HRMY (10)
Institutional Metric AQST HRMY Criterion Row Edge
Market Capitalization
Scale
$465.7M $1.9B Larger Scale HRMY
Trailing P/E Ratio
Valuation
N/M 10.9x Lower Multiple HRMY
Forward P/E Ratio
Valuation
N/M 5.4x Lower Multiple HRMY
Revenue Growth (YoY)
Growth
-41.0% +12.3% Higher Growth HRMY
Operating Margin (TTM)
Profitability
-114.1% 22.2% Higher Margin HRMY
Net Profit Margin
Profitability
-162.3% 18.1% Higher Margin HRMY
Return on Equity (ROE)
Capital Efficiency
0.0% 18.7% Higher ROE HRMY
52-Week Range Position
Momentum
14% ($3–$7) 38% ($26–$43) Stronger Trend HRMY
Beta / 30D Volatility
Risk Regime
0.89β · 56% Vol 0.55β · 38% Vol Lower Realized Risk HRMY
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 67.1 / 100 (BUY) Higher Composite HRMY
Trailing 12M Revenue (USD)
Operating Scale
$49M $989M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% 74.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.9x EV/Rev N/M PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($32M Net Cash) $323M ($498M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HRMY +6.67 pp
AQST: -16.22% · HRMY: -9.55%
3M Horizon HRMY +12.57 pp
AQST: -27.92% · HRMY: -15.35%
6M Horizon HRMY +24.11 pp
AQST: -16.02% · HRMY: +8.09%
1Y Horizon HRMY +38.49 pp
AQST: -40.65% · HRMY: -2.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQST Revenue HRMY Revenue AQST Op. Margin HRMY Op. Margin Margin Leader
FY2018 $70M N/A -72.6% N/A AQST
FY2019 $50M $10M -100.1% -2433.8% AQST
FY2020 $50M $160M -93.6% 10.6% HRMY
FY2021 $50M $310M -68.2% 28.7% HRMY
FY2022 $50M $440M -88.2% 27.4% HRMY
FY2023 $50M $580M -29.9% 33.0% HRMY
FY2024 $60M $710M -53.5% 26.7% HRMY
FY2025 $40M $870M -159.5% 24.0% HRMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HRMY CONSOLIDATION
114d in phase · OBV DISTRIBUTION
Current IV 72.4%
IV Percentile 11th %ile
Put/Call OI Skew 4.40x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HRMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $33.20 · IV 76.7%

HRMY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,320)

Compare $3,320 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 76.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 30d

Net Entry $60 Credit
Max Credit / Yield +$60 (+13.6% RoM)
Max Risk / Buffer -10.5% Cushion ($440 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $35 / $30 Bear Put Spread

Buy 1x $35P · Sell 1x $30P · 30d

Net Entry $230 Debit
T+5d @ -5% Drop +$67 (+29%)
Max Risk / Buffer $230 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HRMY Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 22.2% operating margin.
OpEx & R&D Reinvestment 51.8% of Rev ($512M)
90D Engineering Disclosures 0 Published

Investor FAQ AQST vs HRMY Key Questions & Quantitative Answers

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin), whereas HRMY carries 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin). Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile HRMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HRMY leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with HRMY at +12.3% YoY revenue growth and -6.9% YoY earnings growth on $989M TTM revenue (74.0% gross margin, 22.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AQST cumulative revenue shifted -42.9% while HRMY shifted +8600.0%. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus 51.8% of Rev ($512M) (0 disclosures) for HRMY.

HRMY screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin), whereas HRMY trades at 5.4x Forward P/E, 10.9x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (32.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus HRMY (18.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk). By comparison, HRMY carries 72.4% implied volatility (11th %ile, Compressed (<25th %ile)), a 4.40x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.55β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.